SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 10-Q/A
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1997
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____
Commission file number 0-21379
CUBIST PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 22-3192085
-------- ----------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
24 Emily Street
Cambridge, Massachusetts 02139
------------------------ -----
Address of principal executive offices (Zip Code)
Registrant's telephone number, (617) 576-1999
including area code:
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months, and (2) has been subject to such filing
requirements for the past 90 days.
YES X NO
--- ---
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Common Stock, $.001 par value 10,580,948
----------------------------- ------------------------------
Class Outstanding at August 25, 1998
Explanatory Note
----------------
In response to the comments of the Commission's staff (the "Staff")
by letter dated August 7, 1998, the Company hereby amends its Quarterly
Report on Form 10-Q for the period ended March 31, 1997 as amended by that
certain amendment filed with the Commission on December 12, 1997, by filing
herewith unredacted versions of Exhibits 10.1 and 10.2. Although Confidential
Treatment was requested for the Agreements set forth in the above-referenced
Exhibits, such treatment was not granted because the Agreements terminated
prior to the Staff issuing its final order. The Agreements set forth in the
above-referenced Exhibits have terminated, and are, therefore, no longer
material to the Company's business.
PART II--OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
10.1 Acquisition Option Agreement, dated May 5, 1997, by
and among Novalon Pharmaceutical Corporation, certain
stockholders of Novalon Pharmaceutical Corporation,
and the Applicant (filed herewith)
10.2 Series B Convertible Preferred Stock Purchase
Agreement, dated May 5, 1997, by and between Novalon
Pharmaceutical Corporation and the Applicant (filed
herewith)
11 Statement of Computation of Earnings Per Share
27 Financial Data Schedule
(b) Reports on Form 8-K
No more reports on Form 8-K were filed by the Company during the
quarter ended March 31, 1997.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant had duly caused this report to be signed on its behalf by the
undersigned, thereto duly authorized.
CUBIST PHARMACEUTICALS, INC.
Date: August 26, 1998 By: /s/ Thomas A. Shea
-----------------------------
Thomas A. Shea
Senior Director of Finance and
Administration, Treasurer
(Authorized Officer and Principal
Finance and Accounting Officer)
2